Fasano Underwriting, a Longevity Holdings company, has been a trailblazer in accurate underwriting and life expectancies since its establishment in 1998. Founded by Mike Fasano, the company has evolved into a leading force in the industry, specializing in physician-centric medical assessments.

At the core of Fasano Underwriting’s expertise is a rigorous physician peer reviewed underwriting methodology for life expectancy calculations, coupled with a unique, proprietary mortality table that, unlike the common industry tables. adjusts slope to capture the change from convex to concave survival patterns that develops as the level of impairment increases. This unique approach sets Fasano apart and has resulted in consistently accurate life expectancy estimates, with Actual to Expected accuracy of 97%, 102% and 101% for the trailing 13.5, 10.5 and 5.5 year periods as of June 30, 2023 based on actual, not adjusted, life expectancy estimates.

Fasano Underwriting boasts a cadre of seasoned physicians, nurses and underwriters. With 17 physician Medical Directors and 14 underwriters, the team combines clinical experience with research and insurance medicine expertise. Notably, these professionals bring a wealth of experience from prestigious companies such as New York Life, First Colony Life (Genworth), Legal & General America, and Phoenix Mutual.

Fasano’s areas of specialization encompass cardiology, oncology, pulmonary dysfunction, endocrine disorders, and rheumatology. The company’s solutions are comprehensive and tailored to meet diverse needs, including part or full-time Medical Directors, automated underwriting engine recommendations, underwriting overflow support, life expectancies for life settlements and structured settlements, expert witness services, and life, health, and SPIA underwriting.

With a rich history of over two decades, Fasano Underwriting continues to uphold its commitment to delivering top-notch underwriting solutions, firmly establishing itself as a trusted name in the industry.